Lawrence Biegelsen
Stock Analyst at Wells Fargo
(0.82)
# 3,637
Out of 4,712 analysts
57
Total ratings
40.62%
Success rate
-13.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lawrence Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Overweight | $290 → $305 | $265.68 | +14.80% | 3 | Dec 11, 2024 | |
| NPCE NeuroPace | Upgrades: Overweight | $16 → $20 | $11.35 | +76.21% | 7 | Mar 14, 2024 | |
| NVRO Nevro | Maintains: Equal-Weight | $20 → $17 | $4.05 | +319.75% | 10 | Feb 22, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $116 → $121 | $115.27 | +4.97% | 3 | Dec 13, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $166 → $82 | $37.37 | +119.43% | 5 | Aug 4, 2022 | |
| TFX Teleflex | Downgrades: Equal-Weight | $248 | $180.14 | +37.67% | 1 | Jul 29, 2022 | |
| BDX Becton, Dickinson and Company | Upgrades: Overweight | $275 | $228.12 | +20.55% | 4 | Jun 24, 2022 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $350 → $339 | $538.83 | -37.09% | 2 | Apr 22, 2022 | |
| REE REE Automotive | Initiates: Underweight | $1.5 | $9.00 | -83.33% | 1 | Mar 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $55 → $27 | $6.88 | +292.44% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $124 → $111 | $107.25 | +3.50% | 2 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $144 | $80.57 | +78.42% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $56 | $152.67 | -63.32% | 4 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $74 | $98.44 | -24.83% | 6 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 | $75.92 | +0.99% | 3 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $85 → $90 | $31.90 | +182.13% | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $84.42 | - | 1 | Dec 12, 2019 |
Insulet
Dec 11, 2024
Maintains: Overweight
Price Target: $290 → $305
Current: $265.68
Upside: +14.80%
NeuroPace
Mar 14, 2024
Upgrades: Overweight
Price Target: $16 → $20
Current: $11.35
Upside: +76.21%
Nevro
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $20 → $17
Current: $4.05
Upside: +319.75%
Abbott Laboratories
Dec 13, 2023
Maintains: Overweight
Price Target: $116 → $121
Current: $115.27
Upside: +4.97%
Tandem Diabetes Care
Aug 4, 2022
Maintains: Overweight
Price Target: $166 → $82
Current: $37.37
Upside: +119.43%
Teleflex
Jul 29, 2022
Downgrades: Equal-Weight
Price Target: $248
Current: $180.14
Upside: +37.67%
Becton, Dickinson and Company
Jun 24, 2022
Upgrades: Overweight
Price Target: $275
Current: $228.12
Upside: +20.55%
Intuitive Surgical
Apr 22, 2022
Maintains: Overweight
Price Target: $350 → $339
Current: $538.83
Upside: -37.09%
REE Automotive
Mar 25, 2022
Initiates: Underweight
Price Target: $1.5
Current: $9.00
Upside: -83.33%
Pulmonx
Feb 24, 2022
Maintains: Equal-Weight
Price Target: $55 → $27
Current: $6.88
Upside: +292.44%
Feb 8, 2022
Maintains: Underweight
Price Target: $124 → $111
Current: $107.25
Upside: +3.50%
Jan 19, 2022
Upgrades: Overweight
Price Target: $144
Current: $80.57
Upside: +78.42%
Jan 19, 2022
Upgrades: Equal-Weight
Price Target: $56
Current: $152.67
Upside: -63.32%
Oct 29, 2021
Maintains: Equal-Weight
Price Target: $68 → $74
Current: $98.44
Upside: -24.83%
Apr 28, 2020
Downgrades: Equal-Weight
Price Target: $77
Current: $75.92
Upside: +0.99%
Mar 5, 2020
Upgrades: Overweight
Price Target: $85 → $90
Current: $31.90
Upside: +182.13%
Dec 12, 2019
Upgrades: Overweight
Price Target: n/a
Current: $84.42
Upside: -